Arsenal Bio: Cutting Staff by Half, Not Cells
Arsenal Bio, one of the rare cell therapy companies still swimming in a sea of failed raises, just laid off nearly half its staff. In a sector where funding looks like a unicorn spotted only in biotech myths, Arsenal Bio managed to raise some capital before executing a harsh 50% staff cull. It’s like hosting a party because you found chips, then eating all the guests. This bittersweet survival dance highlights the brutal biotech winter, reminding us that while cells might fight disease, companies clearly don’t fight layoffs. Half the team out, capital precious: Arsenal Bio’s 2024 cell saga, minus the happy ending.
Share the Story
When your company is 'one of the few able to raise funds' but still chops half your team, your business model is basically survival-of-the-fittest meets corporate Hunger Games.
Arsenal Bio raised cash but still slashed half the staff. Nothing says 'biotech innovation' like 'hope you like unemployment.'
Cell therapy startup Arsenal Bio proves even in science, you’re half as likely to keep your job as to get stem cells.
Source: Statnews | Published: 9/17/2025 | Author: Jason Mast
More Articles in Business
CES 2026: The World’s Largest Tech Flex in the Las Vegas Desert
America Adds 50,000 Jobs, But Those 70,000 Stayed Home for Holidays
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Billionaire Bros Move T-Rex LLC Out of California to Avoid Paying Taxes; Dinosaur Surprised
Grandfather Gifts $1,500 with Guest Star Role for Financial Advisor
Facebook Exec Jumps Off Career Cliff to Build Giant iPhone Flop
Man Moves to Spain for Sun, Pays in Airport Commute Hours Instead of Pounds
New Berkshire CEO Gets $25M While Buffett Lived on $100K and Sandwiches
